Decreased expression of EZH2 reactivates RASSF2A by reversal of promoter methylation in breast cancer cells

详细信息    查看全文

• 作者：Pan Yu ; Yawen Guo ; Maimaiti Yusufu ; Zeming Liu ; Shan Wang ; Xingjie Yin ; Gongling Peng ; Longqiang Wang ; Xiangwang Zhao ; Hui Guo ; Tao Huang and Chunping Liu
• 刊名：Cell Biology International
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：40
• 期：10
• 页码：1062-1070
• 全文大小：3612K
• ISSN：1095-8355

文摘

EZH2, the catalytic subunit of polycomb repressor complex 2, has oncogenic properties, whereas RASSF2A, a Ras association domain family protein, has a tumor suppressor role in many types of human cancer. However, the interrelationship between these two genes remains unclear. Here, we showed that the downregulation of EZH2 reduces CpG island methylation of the RASSF2A promoter, thereby leading to increased RASSF2A expression. Our findings also showed that knockdown of EZH2 increased RASSF2A expression in the human breast cancer cell line MCF-7 in cooperation with DNMT1. This was similar to the effect of 5-Aza-CdR, a DNA methylation inhibitor that reactivates tumor suppressor genes and activated RASSF2A expression in our study. The EZH2 inhibitor DZNep markedly suppressed the proliferation, migration, and invasion of MCF-7 cells treated with ADR and TAM. EZH2 inhibits the expression of tumor suppressor gene RASSF2A via promoter hypermethylation. Thus, it plays an important role in tumorigenesis and is a potential therapeutic target for the treatment of breast cancer.